There were relatively small efficacies of evolocumab/alirocumab on the reduction in other lipid variables, including apolipoprotein B and lipoprotein(a), in pediatric patients with HoFH, although the sample sizes were small [19,20]. This evidence concerns the gene APOB and homozygous familial hypercholesterolemia.